Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Biodexa Pharmaceuticals

    MCap

    USD6m

    Last close

    USD1.30

    ▲ 0.58 (79.31%)

    Pharnext

    MCap

    1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    MGI – Media and Games Invest

    MCap

    EUR235m

    Last close

    EUR1.50

    ▲ 0.35 (30.21%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Executive Interview – MISSION Therapeutics

Executive Interview – MISSION Therapeutics

MISSION Therapeutics, a Touchstone Innovations (AIM: IVO) investee company, is a Cambridge-based drug discovery company that is uniquely placed at the forefront of deubiquitylating enzyme (DUB) drug discovery and development. Since inception in 2011, MISSION has built and developed a proprietary chemistry platform and significant know-how in the generation of potent and selective small molecule DUB inhibitors. Ubiquitin is a small protein found in the vast majority of tissues and is involved in numerous cellular processes, including DNA damage and cell proliferation; DUBs are proteases that cleave ubiquitin from protein/other molecules. Hence targeting ubiquitin through the inhibition of DUBs holds the potential to generate novel drugs to treat cancer and other unmet medical needs, including neurodegenerative disease, inflammation, fibrosis, muscle wasting and infectious disease.

< Previous
Next >

You may also be interested in these:

TMT

Checkit – executive interview

Investment Companies

International Public Partnerships - executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free